Unknown

Dataset Information

0

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.


ABSTRACT: Signaling through the immune checkpoint programmed cell death protein-1 (PD-1) enables tumor progression by dampening antitumor immune responses. Therapeutic blockade of the signaling axis between PD-1 and its ligand programmed cell death ligand-1 (PD-L1) with monoclonal antibodies has shown remarkable clinical success in the treatment of cancer. However, antibodies have inherent limitations that can curtail their efficacy in this setting, including poor tissue/tumor penetrance and detrimental Fc-effector functions that deplete immune cells. To determine if PD-1:PD-L1-directed immunotherapy could be improved with smaller, nonantibody therapeutics, we used directed evolution by yeast-surface display to engineer the PD-1 ectodomain as a high-affinity (110 pM) competitive antagonist of PD-L1. In contrast to anti-PD-L1 monoclonal antibodies, high-affinity PD-1 demonstrated superior tumor penetration without inducing depletion of peripheral effector T cells. Consistent with these advantages, in syngeneic CT26 tumor models, high-affinity PD-1 was effective in treating both small (50 mm(3)) and large tumors (150 mm(3)), whereas the activity of anti-PD-L1 antibodies was completely abrogated against large tumors. Furthermore, we found that high-affinity PD-1 could be radiolabeled and applied as a PET imaging tracer to efficiently distinguish between PD-L1-positive and PD-L1-negative tumors in living mice, providing an alternative to invasive biopsy and histological analysis. These results thus highlight the favorable pharmacology of small, nonantibody therapeutics for enhanced cancer immunotherapy and immune diagnostics.

SUBMITTER: Maute RL 

PROVIDER: S-EPMC4664306 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.

Maute Roy L RL   Gordon Sydney R SR   Mayer Aaron T AT   McCracken Melissa N MN   Natarajan Arutselvan A   Ring Nan Guo NG   Kimura Richard R   Tsai Jonathan M JM   Manglik Aashish A   Kruse Andrew C AC   Gambhir Sanjiv S SS   Weissman Irving L IL   Ring Aaron M AM  

Proceedings of the National Academy of Sciences of the United States of America 20151110 47


Signaling through the immune checkpoint programmed cell death protein-1 (PD-1) enables tumor progression by dampening antitumor immune responses. Therapeutic blockade of the signaling axis between PD-1 and its ligand programmed cell death ligand-1 (PD-L1) with monoclonal antibodies has shown remarkable clinical success in the treatment of cancer. However, antibodies have inherent limitations that can curtail their efficacy in this setting, including poor tissue/tumor penetrance and detrimental F  ...[more]

Similar Datasets

| S-EPMC8572878 | biostudies-literature
| S-EPMC4703530 | biostudies-literature
| S-EPMC9147562 | biostudies-literature
| S-EPMC6521698 | biostudies-literature
| S-EPMC7599876 | biostudies-literature
| S-EPMC10324623 | biostudies-literature
| S-EPMC7052809 | biostudies-literature
| S-EPMC8124205 | biostudies-literature
| S-EPMC4955062 | biostudies-literature
| S-EPMC9931671 | biostudies-literature